세계의 줄기세포 제조 시장 : 제품별, 용도별, 유통 채널별, 최종사용자별, 지역별 - 시장 규모, 산업 역학, 기회 분석, 예측(2025-2033년)
Global Stem Cell Manufacturing Market: By Product, Application, Distribution Channel, End Users, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
상품코드:1855044
리서치사:Astute Analytica
발행일:2025년 09월
페이지 정보:영문 421 Pages
라이선스 & 가격 (부가세 별도)
한글목차
줄기세포 제조의 상황은 임상시험의 큰 성공과 재생의료 분야에 변화를 가져올 새로운 치료법의 승인에 힘입어 빠르게 발전하고 있습니다. 이러한 발전은 줄기세포 기술의 치료 가능성을 입증하며 연구자, 투자자, 의료진의 관심과 신뢰를 높이고 있습니다. 그 결과, 시장은 대폭적인 성장을 달성하며, 2024년의 평가액은 약 242억 6,000만 달러에 달했습니다. 이 상승 기조는 앞으로도 계속될 것으로 예상되며, 시장 추산·예측에서는 2033년까지 654억 9,000만 달러로 확대할 것으로 보입니다. 이 성장은 2025-2033년의 예측 기간 중 CAGR 11.96%에 상당하며, 업계내 강력한 기세와 성장 기회의 확대를 강조하고 있습니다.
이러한 급성장의 주요 요인은 전략적 아웃소싱의 급증과 대형 제약사들의 투자 증가에 기인합니다. 줄기세포 치료의 확장성과 비용 효율성이라는 오랜 기간의 제조상의 병목현상을 해결하기 위해서는 이러한 협력과 재정적 지원이 필수적입니다. 전문 수탁제조기관(CMO)과 제휴하고 최첨단 제조기술에 투자함으로써 제약사들은 제조역량을 강화하고 프로세스를 간소화하는 데 주력하고 있습니다. 이러한 전략적 아웃소싱은 업무상 제약이 완화될 뿐만 아니라, 치료제의 상용화 및 세계 시장 출시 속도를 가속화하고 있습니다.
주목할 만한 시장 개발
줄기세포 제조 시장의 주요 기업은 향후 예상되는 수요에 대응하기 위해 대규모 투자를 진행하고 있습니다. 업계 선두 기업인 Lonza는 바카빌 공장에 약 5억 스위스 프랑을 투자했으며, 이 공장은 이미 약 33만 리터 규모의 바이오리액터 용량을 갖추고 있습니다. 이번 대규모 자금 투입은 재생의료 및 세포치료제 개발자들 증가하는 수요에 대응하기 위해 제조 인프라 확충에 전략적으로 집중하고 있는 론자의 의지를 반영하고 있습니다.
마찬가지로 Thermo Fisher Scientific도 연구 및 제조 역량을 강화하기 위해 대담한 움직임을 보이고 있습니다. 이 회사는 연구개발에 14억 달러를 투자하는 한편, 뉴욕에서만 45,000평방피트 이상의 생산기지를 확장하고 있습니다. 이번 확장은 생산 효율성을 높이고 기술 혁신을 가속화하며 줄기세포 치료제 파이프라인을 확장하기 위한 광범위한 전략의 일환입니다. Thermo Fisher의 연구개발 및 물리적 인프라에 대한 헌신은 과학의 발전과 확장 가능한 제조 솔루션의 통합의 중요성을 강조하고 있습니다.
이러한 모멘텀에 더해, 론자는 휴스턴에 30만 평방피트 규모의 새로운 시설을 개발 중으로, 생산 능력 확대에 대한 업계의 적극적인 접근 방식을 더욱 강조하고 있습니다. 이번 확장은 미래의 상업적 수요에 대응하기 위한 Lonza의 헌신을 보여줄 뿐만 아니라, 대량 생산이 가능한 최첨단 시설을 구축하려는 줄기세포 제조 시장의 보다 광범위한 추세를 반영합니다.
핵심 촉진요인
만성질환 증가는 줄기세포 제조를 포함한 재생의료 시장의 성장을 촉진하는 중요한 요인입니다. 당뇨병, 심혈관질환, 신경퇴행성 질환, 자가면역질환 등 만성질환은 전 세계에서 점점 더 흔해져 의료시스템과 환자들에게 큰 부담을 주고 있습니다. 기존 치료법은 근본적인 해결책을 제공하기보다는 증상 관리에 초점을 맞추는 경우가 많아, 손상된 조직을 복구하거나 대체하고 정상 기능을 회복할 수 있는 혁신적인 치료법에 대한 수요가 증가하고 있습니다. 재생의료는 신체 자체의 치유 메커니즘을 활용할 수 있는 가능성을 가지고 있으며, 이러한 미충족 의료 수요에 대응할 수 있는 유망 수단을 제시하고 있습니다.
새로운 비즈니스 기회 동향
인공지능(AI)을 예측적 품질관리(QC)에 통합하면 줄기세포 제조 시장에 혁신의 기회를 가져와 효율성과 제품 신뢰성을 크게 향상시킬 수 있을 것으로 기대됩니다. 줄기세포 제조의 전통적 QC 방법은 수작업 검사나 정기적인 샘플링에 의존하는 경우가 많아 시간이 오래 걸리고, 모순이 발생하기 쉽습니다. 이에 반해 AI를 활용한 시스템은 방대한 데이터를 실시간으로 처리할 수 있는 고도화된 알고리즘을 활용하여 제조 공정의 지속적인 모니터링과 잠재적 문제를 조기에 발견할 수 있습니다. 이 기능은 품질 평가의 정확성을 향상시킬 뿐만 아니라 배치 결함의 위험을 줄이고 전체 생산 수율과 일관성을 향상시킵니다.
최적화를 가로막는 장벽
높은 제조 비용과 줄기세포 치료 특유의 제조 복잡성은 이러한 치료법의 보급을 방해하고 시장 성장을 둔화시킬 수 있는 중대한 문제에 직면해 있습니다. 줄기세포 제조에는 엄격한 품질 기준 준수, 무균 환경, 특수 장비 등을 필요로 하는 복잡한 공정이 포함됩니다. 이러한 요인은 제조 비용 상승으로 이어져 많은 의료 서비스 프로바이더와 환자들에게 치료법을 매우 비싸지게 만들 수 있습니다. 이러한 비용으로 인한 경제적 장벽은 특히 예산이 한정된 지역과 의료 시스템에서 접근성과 채택을 제한하고 있습니다.
목차
제1장 조사 프레임워크
조사 목적
제품 개요
시장 세분화
제2장 조사 방법
정성 조사
1차 정보원·2차 정보원
정량 조사
1차 정보원·2차 정보원
1차 조사 응답자 내역 : 지역별
조사의 전제조건
시장 규모·추산
데이터 삼각측량
제3장 개요 : 세계의 줄기세포 제조 시장
제4장 세계의 줄기세포 제조 시장 개요
산업 밸류체인 분석
재료 프로바이더
제조업체
판매업체
최종사용자
산업 전망
세계의 GDP와 헬스케어 인프라
제약, 바이오테크놀러지, CRO/CDMO의 성장
만성질환 부담의 증대
줄기세포 실험 연구로부터 승인된 임상 치료로의 이동
줄기세포 제조 워크플로우와 신기술
일반적으로 사용되는 줄기세포의 유형
Porter's Five Forces 분석
공급 기업의 교섭력
바이어의 교섭력
대체품의 위협
신규 진출업체의 위협
경쟁 정도
시장 역학과 동향
촉진요인
과제
기회
주요 동향
시장 성장과 전망
시장 매출 추산·예측, 2020-2033년
가격 동향 분석
경쟁 대시보드
시장 집중률
기업 점유율 분석(금액%), 2024년
경쟁 지도제작과 벤치마킹
제5장 세계의 줄기세포 제조 시장 분석 : 제품 유형별
주요 인사이트
시장 규모·예측, 2020-2033년
줄기세포 라인
소모품과 키트
기기
소프트웨어와 서비스
제6장 세계의 줄기세포 제조 시장 분석 : 용도별
주요 인사이트
시장 규모·예측, 2020-2033년
연구 용도
임상 용도
세포·조직은행
제7장 세계의 줄기세포 제조 시장 분석 : 유통 채널별
주요 인사이트
시장 규모·예측, 2020-2033년
직접 판매
유통업체
제8장 세계의 줄기세포 제조 시장 분석 : 최종사용자별
주요 인사이트
시장 규모·예측, 2020-2033년
CRO, 제약, 바이오테크놀러지 기업
학술·연구기관
병원·수술 센터
세포·조직은행
기타 사용자(재생의료 스타트업, 진단 회사)
제9장 세계의 줄기세포 제조 시장 분석 : 지역별
주요 인사이트
시장 규모·예측, 2020-2033년
북미
유럽
아시아태평양
중동 및 아프리카
남미
제10장 북미의 줄기세포 제조 시장 분석
제11장 유럽의 줄기세포 제조 시장 분석
제12장 아시아태평양의 줄기세포 제조 시장 분석
제13장 중동 및 아프리카의 줄기세포 제조 시장 분석
제14장 남미의 줄기세포 제조 시장 분석
제15장 기업 개요
Thermo Fisher Scientific
Lonza
nacalai
BioRad
Merck
FujiFilm
CellGenix
Teknova
Sartorius
Stemcell Technologies
Miltenyi Biotec
Eppendorf
Beckman Coulter
Takara Bio
Bio-Techne
PromoCell
Wellsky
BD
Corning Life Sciences
HiMedia
REPROCELL
Other Prominent Players
제16장 부록
KSA
영문 목차
영문목차
The stem cell manufacturing landscape is evolving rapidly, fueled by significant clinical trial successes and the approval of new therapies that are transforming the regenerative medicine field. These advancements have validated the therapeutic potential of stem cell technologies, driving increased interest and confidence among researchers, investors, and healthcare providers. As a result, the market has experienced substantial growth, with its valuation reaching approximately US$ 24.26 billion in 2024. This upward trajectory is expected to continue, with projections estimating the market will expand to a remarkable US$ 65.49 billion by 2033. This growth corresponds to a compound annual growth rate (CAGR) of 11.96% during the forecast period from 2025 to 2033, underscoring the strong momentum and expanding opportunities within the industry.
A key factor contributing to this rapid expansion is the surge in strategic outsourcing and increased investments from major pharmaceutical companies. These collaborations and financial commitments are crucial in addressing longstanding manufacturing bottlenecks that have challenged the scalability and cost-effectiveness of stem cell therapies. By partnering with specialized contract manufacturing organizations (CMOs) and investing in cutting-edge production technologies, pharmaceutical players are enhancing manufacturing capacity and streamlining processes. This strategic outsourcing not only alleviates operational constraints but also accelerates the pace at which therapies can be commercialized and brought to market on a global scale.
Noteworthy Market Developments
Leading corporations in the stem cell manufacturing market are making substantial investments to position themselves for anticipated future demand, signaling a robust commitment to scaling production capabilities and advancing the field. Lonza, a key player in the industry, is investing approximately 500 million Swiss francs into its Vacaville facility, which already features an impressive bioreactor capacity of around 330,000 liters. This significant financial commitment reflects Lonza's strategic focus on expanding its manufacturing infrastructure to meet the growing needs of regenerative medicine and cell therapy developers.
Similarly, Thermo Fisher Scientific is making bold moves to enhance its research and manufacturing capabilities. The company is investing $1.4 billion in research and development, alongside expanding its manufacturing footprint by more than 45,000 square feet in New York alone. This expansion is part of a broader strategy to increase production efficiency, accelerate innovation, and support a growing pipeline of stem cell therapies. Thermo Fisher's commitment to both R&D and physical infrastructure highlights the critical importance of integrating scientific advancement with scalable manufacturing solutions.
Adding to this momentum, Lonza is also developing a new 300,000-square-foot facility in Houston, further emphasizing the industry's aggressive approach to scaling capacity. This expansion not only demonstrates Lonza's dedication to meeting future commercial demand but also reflects a broader trend within the stem cell manufacturing market toward building state-of-the-art facilities capable of supporting high-volume production.
Core Growth Drivers
The rising prevalence of chronic diseases is a significant factor driving the growth of the regenerative medicine market, including stem cell manufacturing. Chronic illnesses such as diabetes, cardiovascular diseases, neurodegenerative disorders, and autoimmune conditions have become increasingly common worldwide, placing a substantial burden on healthcare systems and patients alike. Traditional treatment options often focus on managing symptoms rather than offering curative solutions, leading to a growing demand for innovative therapies that can repair or replace damaged tissues and restore normal function. Regenerative medicine, with its potential to harness the body's own healing mechanisms, presents a promising avenue for addressing these unmet medical needs.
Emerging Opportunity Trends
The integration of artificial intelligence (AI) into predictive quality control (QC) represents a transformative opportunity for the stem cell manufacturing market, promising to significantly enhance efficiency and product reliability. Traditional QC methods in stem cell manufacturing often rely on manual inspections and periodic sampling, which can be time-consuming and prone to inconsistencies. In contrast, AI-driven systems leverage advanced algorithms capable of processing vast amounts of data in real time, allowing for continuous monitoring and early detection of potential issues during the manufacturing process. This capability not only improves the accuracy of quality assessments but also reduces the risk of batch failures, thereby increasing overall manufacturing yield and consistency.
Barriers to Optimization
High manufacturing costs and the inherent complexity of producing stem cell therapies pose significant challenges that could impede the widespread adoption of these treatments and potentially slow market growth. Stem cell manufacturing involves intricate processes that demand strict adherence to quality standards, sterile environments, and specialized equipment. These factors contribute to elevated production expenses, which in turn can make therapies prohibitively expensive for many healthcare providers and patients. The financial barrier created by these costs limits accessibility and adoption, especially in regions or healthcare systems with constrained budgets.
Detailed Market Segmentation
By Product Type, the consumables and kits segment holds a crucial position within the stem cell manufacturing market, commanding a substantial revenue share of 42.51%. This segment forms the backbone of the entire industry, as consumables and kits are indispensable at every stage of the stem cell lifecycle-from initial research and development to scale-up and commercial production. The recurring nature of demand for these products stems from their essential role in maintaining cell viability, supporting cell growth, and ensuring the precision required for consistent manufacturing outcomes. Without reliable and high-quality consumables, the entire process of stem cell manufacturing would face significant challenges, making this segment foundational to the industry's overall success.
By Distribution Channel, the direct sales channel dominates the stem cell manufacturing market, generating over 69.93% of the total market revenue. This overwhelming share is largely attributed to the highly sensitive and complex nature of stem cell products, which demand specialized handling and distribution processes. Unlike conventional pharmaceutical products, stem cell therapies are living biological materials that require precise conditions to maintain their viability and therapeutic efficacy. The intricate nature of these products necessitates direct interaction between manufacturers and end-users, such as hospitals, clinics, and research institutions, ensuring strict quality control and compliance with regulatory standards throughout the supply chain.
By End Users, Pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) are controlling the largest 44.67% market share. There are a few companies that hold the dominant position in the market, but they are collectively the commercial engine of the industry. These entities in the stem cell manufacturing market possess the financial resources, infrastructure, and regulatory expertise necessary to navigate the long and expensive path from research to commercialization.
By Application, the clinical applications segment holds a commanding position within the stem cell manufacturing market, accounting for 52.32% of the total market share. This significant share reflects the critical role clinical applications play in transforming the scientific potential of stem cell research into real-world medical treatments. As the field of regenerative medicine continues to advance, clinical applications serve as the primary avenue through which promising laboratory discoveries are translated into therapies that can improve patient outcomes. The emphasis on clinical use underscores the growing confidence in stem cell technologies as viable treatment options for a range of diseases and conditions.
Segment Breakdown
By Product
Stem Cell Lines
Mesenchymal Stem Cells
Differentiated
Instruments
Bioreactors & Cell Expansion Systems
Cell Sorters & Separation Devices
Flow Cytometers & Analysers
Consumables and Kits
Culture Media
Growth Factors & Cytokines
Culture ware and Vessels
Undifferentiated
Instruments
Bioreactors & Cell Expansion Systems
Cell Sorters & Separation Devices
Flow Cytometers & Analysers
Consumables and Kits
Culture Media
Growth Factors & Cytokines
Culture ware and Vessels
Induced Pluripotent Stem Cells
Differentiated
Instruments
Bioreactors & Cell Expansion Systems
Cell Sorters & Separation Devices
Flow Cytometers & Analysers
Consumables and Kits
Culture Media
Growth Factors & Cytokines
Culture ware and Vessels
Undifferentiated
Instruments
Bioreactors & Cell Expansion Systems
Cell Sorters & Separation Devices
Flow Cytometers & Analysers
Consumables and Kits
Culture Media
Growth Factors & Cytokines
Culture ware and Vessels
Hematopoietic Stem Cells
Differentiated
Instruments
Bioreactors & Cell Expansion Systems
Cell Sorters & Separation Devices
Flow Cytometers & Analysers
Consumables and Kits
Culture Media
Growth Factors & Cytokines
Culture ware and Vessels
Undifferentiated
Instruments
Bioreactors & Cell Expansion Systems
Cell Sorters & Separation Devices
Flow Cytometers & Analysers
Consumables and Kits
Culture Media
Growth Factors & Cytokines
Culture ware and Vessels
Embryonic Stem Cells
Differentiated
Instruments
Bioreactors & Cell Expansion Systems
Cell Sorters & Separation Devices
Flow Cytometers & Analysers
Consumables and Kits
Culture Media
Growth Factors & Cytokines
Culture ware and Vessels
Undifferentiated
Instruments
Bioreactors & Cell Expansion Systems
Cell Sorters & Separation Devices
Flow Cytometers & Analysers
Consumables and Kits
Culture Media
Growth Factors & Cytokines
Culture ware and Vessels
Neural Stem Cells
Differentiated
Instruments
Bioreactors & Cell Expansion Systems
Cell Sorters & Separation Devices
Flow Cytometers & Analysers
Consumables and Kits
Culture Media
Growth Factors & Cytokines
Culture ware and Vessels
Undifferentiated
Instruments
Bioreactors & Cell Expansion Systems
Cell Sorters & Separation Devices
Flow Cytometers & Analysers
Consumables and Kits
Culture Media
Growth Factors & Cytokines
Culture ware and Vessels
Others
Differentiated
Instruments
Bioreactors & Cell Expansion Systems
Cell Sorters & Separation Devices
Flow Cytometers & Analysers
Consumables and Kits
Culture Media
Growth Factors & Cytokines
Culture ware and Vessels
Undifferentiated
Instruments
Bioreactors & Cell Expansion Systems
Cell Sorters & Separation Devices
Flow Cytometers & Analysers
Consumables and Kits
Culture Media
Growth Factors & Cytokines
Culture ware and Vessels
Consumables and Kits
By Type
Culture Media
Growth Factors & Cytokines
Culture ware and Vessels
T-Flasks
Vials
Cell Culture Dishes / Multi-Well Plates
Cell Culture Bags
Others
Others
By Application
Research Applications
Disease Modelling
Drug Discovery & Toxicology Testing
Others
Clinical Applications
Autologous Therapies
Allogeneic Therapies
Cell & Tissue Banking
Instruments
Bioreactors & Cell Expansion Systems
Cell Sorters & Separation Devices
Flow Cytometers & Analysers
Software and Services
By Application
Research Applications
Disease Modelling
Drug Discovery & Toxicology Testing
Others
Clinical Applications
Autologous Therapies
Allogeneic Therapies
Cell & Tissue Banking
By Distribution Channel
Direct Sales
Distributors
By End User
CROs, Pharmaceutical and Biotechnology Companies
Academic & Research Institutions
Hospitals & Surgical Centres
Cell & Tissue Banks
Other Users (Regenerative Medicine Startups, Diagnostic Firms)
By Region
North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
South Korea
Australia & New Zealand
ASEAN
Cambodia
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Argentina
Brazil
Rest of South America
Geography Breakdown
North America stands out as the undisputed global leader in the stem cell manufacturing market, propelled by a strong blend of well-established regulatory frameworks, significant public funding, and a thriving biotechnology ecosystem. The region's dominance is anchored by its ability to create a conducive environment for research, development, and commercialization of stem cell technologies. Regulatory agencies in the United States and Canada have developed clear and structured pathways that facilitate the approval and oversight of stem cell products, giving companies the confidence to invest heavily in innovation and scale-up manufacturing capabilities. This regulatory clarity is a critical factor that distinguishes North America from other regions, reducing uncertainties and accelerating the time to market for new therapies.
The market's anticipated share of over 49.58% by 2033 highlights North America's commanding presence in the industry. This leading position is reinforced by the substantial financial resources directed toward stem cell research and manufacturing infrastructure. Both federal and state governments in the U.S. have launched initiatives and funding programs that support biotechnology ventures, clinical trials, and manufacturing advancements. These investments not only stimulate industry growth but also foster collaboration between academia, private companies, and healthcare providers.
Leading Market Participants
Thermo Fisher Scientific
Lonza
nacalai
BioRad
Merck
FujiFilm
CellGenix
Teknova
Sartorius
Stemcell Technologies
Miltenyi Biotec
Eppendorf
Beckman Coulter
Takara Bio
Bio-Techne
PromoCell
Wellsky
BD
Corning Life Sciences
HiMedia
REPROCELL
Other Prominent Players
Table of Content
Chapter 1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
Chapter 2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Sources
2.2. Quantitative Research
2.2.1. Primary & Secondary Sources
2.3. Breakdown of Primary Research Respondents, By Region
2.4. Assumption for the Study
2.5. Market Size Estimation
2.6. Data Triangulation
Chapter 3. Executive Summary: Global Stem Cell Manufacturing Market
Chapter 4. Global Stem Cell Manufacturing Market Overview
4.1. Industry Value Chain Analysis
4.1.1. Material Provider
4.1.2. Manufacturer
4.1.3. Distributor
4.1.4. End User
4.2. Industry Outlook
4.2.1. Global GDP and Healthcare Infrastructure
4.2.2. Growth in Pharmaceutical, Biotechnology, and CRO/CDMO
4.2.3. Growing Chronic Disease Burden
4.2.4. Transition from Stem Cell Experimental Research to Approved Clinical Therapies
4.2.5. Stem Cell Manufacturing Workflow and Emerging Technologies
4.2.5.1. Embryonic Stem Cells (ESCs)
4.2.5.2. Induced Pluripotent Stem Cells (iPSCs)
4.2.5.3. Adult Stem Cells (ASCs)
4.2.6. Commonly Used Stem Cell Types
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of Substitutes
4.3.4. Threat of New Entrants
4.3.5. Degree of Competition
4.4. Market Dynamics and Trends
4.4.1. Growth Drivers
4.4.2. Challenges
4.4.3. Opportunity
4.4.4. Key Trends
4.5. Market Growth and Outlook
4.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2033
4.5.2. Price Trend Analysis
4.6. Competition Dashboard
4.6.1. Market Concentration Rate
4.6.2. Company Market Share Analysis (Value %), 2024
4.6.3. Competitor Mapping & Benchmarking
Chapter 5. Global Stem Cell Manufacturing Market Analysis, By Product Type
5.1. Key Insights
5.2. Market Size and Forecast, 2020-2033 (US$ Mn)
5.2.1. Stem Cell Lines
5.2.1.1. Mesenchymal Stem Cells
5.2.1.1.1. Differentiated
5.2.1.1.1.1. Instruments
5.2.1.1.1.1.1. Bioreactors & Cell Expansion Systems
5.2.1.1.1.1.2. Cell Sorters & Separation Devices
5.2.1.1.1.1.3. Flow Cytometers & Analysers
5.2.1.1.1.2. Consumables and Kits
5.2.1.1.1.2.1. Culture Media
5.2.1.1.1.2.2. Growth Factors & Cytokines
5.2.1.1.1.2.3. Culture ware and Vessels
5.2.1.1.2. Undifferentiated
5.2.1.1.2.1. Instruments
5.2.1.1.2.1.1. Bioreactors & Cell Expansion Systems
5.2.1.1.2.1.2. Cell Sorters & Separation Devices
5.2.1.1.2.1.3. Flow Cytometers & Analysers
5.2.1.1.2.2. Consumables and Kits
5.2.1.1.2.2.1. Culture Media
5.2.1.1.2.2.2. Growth Factors & Cytokines
5.2.1.1.2.2.3. Culture ware and Vessels
5.2.1.2. Induced Pluripotent Stem Cells
5.2.1.2.1. Differentiated
5.2.1.2.1.1. Instruments
5.2.1.2.1.1.1. Bioreactors & Cell Expansion Systems
5.2.1.2.1.1.2. Cell Sorters & Separation Devices
5.2.1.2.1.1.3. Flow Cytometers & Analysers
5.2.1.2.1.2. Consumables and Kits
5.2.1.2.1.2.1. Culture Media
5.2.1.2.1.2.2. Growth Factors & Cytokines
5.2.1.2.1.2.3. Culture ware and Vessels
5.2.1.2.2. Undifferentiated
5.2.1.2.2.1. Instruments
5.2.1.2.2.1.1. Bioreactors & Cell Expansion Systems
5.2.1.2.2.1.2. Cell Sorters & Separation Devices
5.2.1.2.2.1.3. Flow Cytometers & Analysers
5.2.1.2.2.2. Consumables and Kits
5.2.1.2.2.2.1. Culture Media
5.2.1.2.2.2.2. Growth Factors & Cytokines
5.2.1.2.2.2.3. Culture ware and Vessels
5.2.1.3. Hematopoietic Stem Cells
5.2.1.3.1. Differentiated
5.2.1.3.1.1. Instruments
5.2.1.3.1.1.1. Bioreactors & Cell Expansion Systems
5.2.1.3.1.1.2. Cell Sorters & Separation Devices
5.2.1.3.1.1.3. Flow Cytometers & Analysers
5.2.1.3.1.2. Consumables and Kits
5.2.1.3.1.2.1. Culture Media
5.2.1.3.1.2.2. Growth Factors & Cytokines
5.2.1.3.1.2.3. Culture ware and Vessels
5.2.1.3.2. Undifferentiated
5.2.1.3.2.1. Instruments
5.2.1.3.2.1.1. Bioreactors & Cell Expansion Systems
5.2.1.3.2.1.2. Cell Sorters & Separation Devices
5.2.1.3.2.1.3. Flow Cytometers & Analysers
5.2.1.3.2.2. Consumables and Kits
5.2.1.3.2.2.1. Culture Media
5.2.1.3.2.2.2. Growth Factors & Cytokines
5.2.1.3.2.2.3. Culture ware and Vessels
5.2.1.4. Embryonic Stem Cells
5.2.1.4.1. Differentiated
5.2.1.4.1.1. Instruments
5.2.1.4.1.1.1. Bioreactors & Cell Expansion Systems
5.2.1.4.1.1.2. Cell Sorters & Separation Devices
5.2.1.4.1.1.3. Flow Cytometers & Analysers
5.2.1.4.1.2. Consumables and Kits
5.2.1.4.1.2.1. Culture Media
5.2.1.4.1.2.2. Growth Factors & Cytokines
5.2.1.4.1.2.3. Culture ware and Vessels
5.2.1.4.2. Undifferentiated
5.2.1.4.2.1. Instruments
5.2.1.4.2.1.1. Bioreactors & Cell Expansion Systems
5.2.1.4.2.1.2. Cell Sorters & Separation Devices
5.2.1.4.2.1.3. Flow Cytometers & Analysers
5.2.1.4.2.2. Consumables and Kits
5.2.1.4.2.2.1. Culture Media
5.2.1.4.2.2.2. Growth Factors & Cytokines
5.2.1.4.2.2.3. Culture ware and Vessels
5.2.1.5. Neural Stem Cells
5.2.1.5.1. Differentiated
5.2.1.5.1.1. Instruments
5.2.1.5.1.1.1. Bioreactors & Cell Expansion Systems
5.2.1.5.1.1.2. Cell Sorters & Separation Devices
5.2.1.5.1.1.3. Flow Cytometers & Analysers
5.2.1.5.1.2. Consumables and Kits
5.2.1.5.1.2.1. Culture Media
5.2.1.5.1.2.2. Growth Factors & Cytokines
5.2.1.5.1.2.3. Culture ware and Vessels
5.2.1.5.2. Undifferentiated
5.2.1.5.2.1. Instruments
5.2.1.5.2.1.1. Bioreactors & Cell Expansion Systems
5.2.1.5.2.1.2. Cell Sorters & Separation Devices
5.2.1.5.2.1.3. Flow Cytometers & Analysers
5.2.1.5.2.2. Consumables and Kits
5.2.1.5.2.2.1. Culture Media
5.2.1.5.2.2.2. Growth Factors & Cytokines
5.2.1.5.2.2.3. Culture ware and Vessels
5.2.1.6. Others
5.2.1.6.1. Differentiated
5.2.1.6.1.1. Instruments
5.2.1.6.1.1.1. Bioreactors & Cell Expansion Systems
5.2.1.6.1.1.2. Cell Sorters & Separation Devices
5.2.1.6.1.1.3. Flow Cytometers & Analysers
5.2.1.6.1.2. Consumables and Kits
5.2.1.6.1.2.1. Culture Media
5.2.1.6.1.2.2. Growth Factors & Cytokines
5.2.1.6.1.2.3. Culture ware and Vessels
5.2.1.6.2. Undifferentiated
5.2.1.6.2.1. Instruments
5.2.1.6.2.1.1. Bioreactors & Cell Expansion Systems
